AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03106181 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Phacoemulsification and intraocular lens implant
Description: Conventional phacoemulsification cataract surgery and intraocular lens implant
Study NCT03106181 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Phacoemulsification and intraocular lens implant
Description: Conventional phacoemulsification cataract surgery and intraocular lens implant
Study NCT00799279 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking cessation training, support, and telephone follow-up
Description: The CF group will receive the same smoking cessation training and practice support tools delivered to the PS group. In addition, patients in the FC group who are smokers and are willing to set a quit date within the next 30 days and who have set a quit date will be enrolled in an interactive voice response (IVR)-mediated telephone follow-up and counselling system. The IVR system will automatically contact patients via telephone 7 days before their TQD, and 5, 14, 30, and 60 days after their TQD to check the patients' smoking status, potential concerns, and their risk of relapse.
Study NCT00799279 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: smoking cessation intervention
Description: Intervention practices will be provided with training in smoking cessation, and will be supported with integrating a waiting room screener for smoking and smoking consult form and patient quit plan into their practice routines.
Study NCT02686021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metamizole and Ibuprofen
Description: Metamizole (1000mg) plus Ibuprofen (400mg) 15 minutes prior to surgery, at 6 postoperative hours, and at 12 postoperative hours
Study NCT02686021 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metamizole and Placebo
Description: Metamizole (1000mg) plus placebo 15 minutes prior to surgery, at 6 postoperative hours, and at 12 postoperative hours
Study NCT02686021 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen and Placebo
Description: Ibuprofen (400mg) plus placebo 15 minutes prior to surgery, at 6 postoperative hours, and at 12 postoperative hours
Study NCT00818389 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lithium Carbonate
Description: Participants will receive capsules that contain 150 milligrams (mg) lithium carbonate. Participants will be randomized to lithium/riluzole or placebo/riluzole and treated for 52 weeks. Participants originally randomized to placebo who fail (progress) will crossover to lithium for the remainder of the trial.
Study NCT00818389 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Riluzole
Description: All participants enrolled in this study will be taking a stable dose of riluzole 50 milligrams (mg) by mouth (PO) twice per day (BID) for at least 30 days prior to screening.
Study NCT00818389 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Riluzole
Description: All participants enrolled in this study will be taking a stable dose of riluzole 50 milligrams (mg) by mouth (PO) twice per day (BID) for at least 30 days prior to screening.
Study NCT00818389 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: an inactive substance
Study NCT03399409 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: Motivation techniques
Study NCT03399409 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Anti-inflammatory Information
Description: Provision of information on anti-inflammatory products
Study NCT01893229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium
Description: Lithium is used as a mood stabiliser
Study NCT01893229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproate
Description: Valproate is used as a mood stabiliser
Study NCT01893229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine
Description: Oxcarbazepine is used as a mood stabiliser
Study NCT01893229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine
Description: Quetiapine is used as a mood stabiliser
Study NCT01893229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: Olanzapine is used as a mood stabiliser.
Study NCT01893229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Description: Ziprasidone is used as a mood stabiliser
Study NCT02041260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Study NCT02076217 — intervention group
Intervention type: DRUG
Intervention: Copper T-380 IUD
Study NCT02076217 — intervention group
Intervention type: DRUG
Intervention: LNG IUD
Study NCT02076217 — intervention group
Intervention type: DEVICE
Intervention: Contraceptive implant Nexplanon
Study NCT02076217 — intervention group
Intervention type: DRUG
Intervention: Depo-Provera
Study NCT00669487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZT/3TC/NVP, AZT/D4T/NVP, Truvada/NVP
Description: Truvada(FTC200mg+TDF300mg) every 24 hours + NVP 200 mg every 12 hours orally until week 72
Study NCT00669487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZT/3TC/NVP, AZT/D4T/NVP, Truvada/NVP
Description: GPO-VIR S(D4T30mg+3TC150mg+NVP200mg)1 pill orally every 12 hours until week 24 and then switch to GPO-VIR Z
Study NCT00669487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZT/3TC/NVP, AZT/D4T/NVP, Truvada/NVP
Description: GPO-VIR Z(AZT250mg+3TC150mg+NVP200mg) 1 pill orally every 12 hours until week 72
Study NCT03331653 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry Needling and Ischemic Compression at the Trigger Point
Description: The intervention consist on dry needling in the active trigger point, and next, do ischemic compression in the same point.
Study NCT03331653 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dry Needling and Ischemic Compression at 1.5 centimeters from the Trigger Point
Description: The intervention consist on dry needling at 1.5 centimeters from the active trigger point, and next, do ischemic compression in the same point.
Study NCT01241552 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-3415
Description: A single IV infusion of MK-3415 (10 mg/kg of monoclonal antibody to Clostridium difficile Toxin A)
Study NCT01241552 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-6072
Description: A single infusion of MK-6072 (10 mg/kg of monoclonal antibody to Clostridium difficile Toxin B)
Study NCT01241552 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-3415A
Description: A single IV infusion of MK-3415A (10 mg/kg of monoclonal antibody to Clostridium difficile Toxin A and 10mg/kg of monoclonal antibody to Clostridium difficile Toxin B)
Study NCT01241552 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single IV infusion of normal saline (0.9% sodium chloride)
Study NCT01241552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOC
Description: Standard of care (SOC) for CDI will be prescribed for 10 to 14 days and can begin on the day of study drug infusion; but the first dose must have been administered prior to or within a few hours following study drug infusion. SOC is defined as the receipt of oral metranidazole, oral vancomycin, IV metronidazole concurrent with oral vancomycin, oral fidaxomicin, or oral fidaxomicin concurrent with IV metronidazole.
Study NCT01241552 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SOC
Description: Standard of care (SOC) for CDI will be prescribed for 10 to 14 days and can begin on the day of study drug infusion; but the first dose must have been administered prior to or within a few hours following study drug infusion. SOC is defined as the receipt of oral metranidazole, oral vancomycin, IV metronidazole concurrent with oral vancomycin, oral fidaxomicin, or oral fidaxomicin concurrent with IV metronidazole.
Study NCT00908063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycyte
Description: A single dose of one of three dosage levels (dose escalating design), given by intravenous infusion at the rate of 15 mL/min (total duration expected to be between 5 and 20 minutes).
Study NCT00908063 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Normal saline will be administered as one of three volume doses based on cohort assignment (1.0 mL/min; 2.0 mL/min; 3.0 mL/min). The infusion will be administered at a rate of 15mL/min and will begin within 12 hours of injury.
Study NCT04004429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50 mg AP1189
Description: 50 mg AP1189 powder in bottle
Study NCT04004429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AP1189
Description: 100 mg AP1189 powder in bottle
Study NCT04004429 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo powder in bottle
Study NCT00912652 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: lifestyle intervention
Description: Three doses of lifestyle intervention will be compared to an education control condition.
Study NCT00912652 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education Control
Description: Health education control group will receive 16 session of health education related to diet and exercise over a two-year period.
Study NCT03631745 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NAMI Mental Health 101 and NAMI FaithNet
Description: Congregants of Intervention Churches will receive:~1. NAMI Mental Health 101, a 60-90 minute, contact-based educational intervention~2. NAMI FaithNet which consists of congregational support and training to cultivate supportive environments within faith communities for those with mental health conditions and their families.
Study NCT01526551 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HPV Vaccine and HPV-related Health Education
Description: Increased education of HPV-related diseases and HPV vaccine
Study NCT01526551 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reduction of barriers
Description: Eliminate structural and financial barriers to being vaccinated
Study NCT04589182 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MHSL- SleepBand
Description: The MHSL-SleepBand (sleep headband) is easy to apply and only involves attachment of sticky electrodes on different locations on the face/behind ear to be able to measure EEG (electroencephalogram), EOG (electrooculogram) and EMG (electromyogram). Brief tones at a low volume (around 60 dB, comparable to conversation) will be applied, when slow waves are present in the course of the sleep period and other criteria are fulfilled. Auditory stimulation will start with a specific volume that has been adjusted to the individual hearing capacity (usually between 45-65 dB; maximum 80 dB). The stimulation is performed in a way that the general structure of sleep (e.g. duration, sleep cycling, etc.) is unchanged.
Study NCT04589182 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Playing no tones during non- Rapid Eye Movement (NREM) sleep but wearing the device and recording the biosignals over a period of 3 nights, every night.
Study NCT01200108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Study NCT01200108 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide
Study NCT02939872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aspirin and clopidogrel
Description: at the discretion of investigator
Study NCT02939872 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel only
Description: at the discretion of investigator
Study NCT04111965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nanodrop®
Description: minimum to meet 1 drop 4 times a day, both eyes
Study NCT04111965 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Systane Balance
Description: minimum to meet 1 drop 4 times a day, both eyes
Study NCT02740296 — intervention group
Intervention type: OTHER
Intervention: No intervention
Study NCT01919320 — intervention group
Intervention type: DEVICE
Intervention: C2 Driver System TAH-t Patients
Description: Comparison of two pneumatic drivers supporting the SynCardia TAH-t
Study NCT01919320 — intervention group
Intervention type: DEVICE
Intervention: CSS Console TAH-t Patients
Description: Comparison of two pneumatic drivers supporting the SynCardia TAH-t.
Study NCT02540863 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: myofascial release protocol and Rocabado exercise therapy
Study NCT02540863 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercise therapy
Study NCT01622179 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: sewed indirectly
Description: The epitenon was repaired and sewed indirectly.
Study NCT01622179 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: sewed directly
Description: The epitenon was unrepaired and sewed directly.
Study NCT04225468 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACL Opioid Exposure Reduction Program
Description: Subjects will engage in a brief, educational which includes information about the appropriate use of opioid pain medication, exposure and tolerance, the definition of misuse and opioid-related harms, how to wean off medication, alternative pain management strategies, and appropriate disposal of leftover medication.
Study NCT03971656 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional Supplement
Description: Oral nutritional supplementation
Study NCT03971656 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Preoperative Dietitian Consult
Description: Nutritional assessment
Study NCT03971656 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Informational materials about nutrition
Study NCT02251925 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: frozen Embryo transfer
Description: In this study all patients who will undergo frozen embryo transfer are randomly allocated to be prepared for transfer by using either natural cycle (with or without hCG for ovulation induction) or Hormonal cycle (with or without administration of GnRH-a).
Study NCT02251925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10,000U hCG injection
Description: In natural cycle with hCG, after detection of mature follicles in ultrasound and endometrial thickness over 7mm, 10,000IU hCG is injected for ovulation and embryo transfer is performed 3-5 days later in cleavage stage.
Study NCT02251925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRH agonist (Superfact)
Description: In group 3, injection of GnRH agonist (Superfact) at a subcutaneous daily dose of 0.5 mg is started on the day 17-19 of the natural menstrual cycle. Once pituitary desensitization is confirmed, hormonal treatment is commenced with 4mg/day oral Estradiol valerate and after 7 days if endometrial thickness is adequate, Estradiol administration will be continued with the same dose and 100mg Progesterone is administered before embryo transfer, otherwise patients are candidates for higher dosage of Estradiol till favourable endometrial thickness is achieved.
Study NCT02251925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: administration of 6 mg Estradiol valerate
Description: In the hormonal group without GnRH-a, endometrial preparation will be started with daily administration of 6 mg Estradiol valerate from the 2nd day of the natural menstrual cycle for 6 days. Then treatment will be continued similar to the 3rd group.
Study NCT02906345 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Plasma Exchange (TPE)
Description: All treated patients should treated two (minimal) to five times by TPE, depending on the need of norephinephrine for the therapy. For each session 40 ml/kg body weight plasma should be exchange. Fluid resuscitation will be done with fresh frozen plasma.
Study NCT01617850 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supervised physical exercise training x3 weekly for 12 weeks
Description: Physical exercise training 1 hour per session. The exercise rehabilitation programme is carried out as group training with individual supervision. At each exercise session two experienced physiotherapist are leading the physical exercise training. Standardized physical exercise guidelines for each training session is described and followed. It consists of the following interventions: Warm up, aerobe fitness, muscle strength training and individual education and instruction in life stills changes in relation to physical activity.
Study NCT01617850 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supervised physical exercise training x2 weekly for 8 weeks
Description: Physical exercise training is carried out for 1 hour per session. The exercise rehabilitation programme is carried out as group training with individual supervision. At each exercise session two-experienced physiotherapist are leading the physical exercise training. Standardized physical exercise guidelines for each training session is described and followed. It consists of the following interventions: Warm up, aerobe fitness, muscle strength training and individual education and instruction in life stills changes in relation to physical activity.
Study NCT01558583 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Rating and Ranking Task
Description: Individuals who are randomized to the rating and raking arm will be asked to complete an informational task in a rating and ranking format. The task will help individuals clarify their opinions and preferences regarding colon cancer and prostate cancer screening.
Study NCT01558583 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Discrete Choice Task
Description: Individuals who are randomized to the rating and raking arm will be asked to complete an informational task in a discrete choice format. The task will help individuals clarify their opinions and preferences regarding colon cancer and prostate cancer screening.
Study NCT01558583 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Balance Sheet Task
Description: Individuals who are randomized to the rating and raking arm will be asked to complete an informational task in a balance sheet format. The task will help individuals clarify their opinions and preferences regarding colon cancer and prostate cancer screening.
Study NCT01088191 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MSB-CAR001 Combined With Hyaluronan
Description: Knee Injection of Biological: MSB-CAR001 Combined With Hyaluronan~Single Injection Into the Knee Joint of Single Doses of MSB-CAR001 Combined With Hyaluronan
Study NCT01088191 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSB-CAR001 Combined With Hyaluronan
Description: Knee Injection of Biological: MSB-CAR001 Combined With Hyaluronan~Single Injection Into the Knee Joint of Single Doses of MSB-CAR001 Combined With Hyaluronan
Study NCT01088191 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronan
Description: Hyaluronan alone
Study NCT00931944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KNS-760704
Description: 150 mg Q12H KNS-760704 given orally (300 mg total daily dose)
Study NCT03858452 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Muscles exercises program
Study NCT02564107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibandronate
Description: Participants will receive ibandronate, 50 milligrams (mg) by mouth every morning, for a period of 25 weeks.
Study NCT00239226 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IAS pacing - study group
Description: site of implant and permanent pacing
Study NCT00239226 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IAS pacing control group
Description: site of implant and permanent pacing
Study NCT00239226 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pacing RAA study group
Description: site of implant and permanent pacing
Study NCT00239226 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pacing RAA control group
Description: site of implant and permanent pacing
Study NCT02225717 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cervicovaginal swab
Description: Sample of cervicovaginal secretions made by the surgical team using a sterile swab introduced directly into the posterior fornix of vagina for one minute during the insertion of the urinary catheter
Study NCT02236884 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: no-scar transanal total mesorectal excision(TME)
Study NCT02187614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac
Study NCT02187614 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Study NCT02187614 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Study NCT02187614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Study NCT02187614 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebos
Study NCT04653168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3041658
Description: Administered SC
Study NCT02939755 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stepped collaborative care intervention
Description: Using website that was specifically designed for advanced cancer patient, collaborative with treatment from health professional
Study NCT02939755 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: usual care from health providers